FGF23 and Iron Deficiency

The BIOMEDICA FGF23 ELISA assays were recently used in a study investigating hepcidin and iron status in patients with inflammatory bowel disease undergoing therapy (1). Hepcidin, a peptide produced by liver cells, plays a vital role in regulating the body´s iron levels. In instances of inflammation, circulating hepcidin levels rise. Inflammation and iron deficiency have also been shown to stimulate FGF23 production (2). Iron deficiency enhances both the transcription and post-translational cleavage of FGF23 (3). Typically, this results in increased serum FGF23 C-terminal levels, with little to no effect on the biologically active intact FGF23 concentrations (4).

About FGF23

Fibroblast growth factor 23 (FGF23) is a protein that plays a crucial role in regulating phosphate and vitamin D metabolism in the body.

It is primarily produced by bone cells in the tissue called osteocytes. FGF 23 acts on the kidneys and decreases phosphate reabsorption thereby preventing the excessive accumulation of phosphate in the body.

Inflammatory bowel disease and FGF23

Patients with inflammatory bowel disease (IBD) face a greater risk to develop osteopenia and osteoporosis compared to the general population (5). In a study investigating the role of FGF23 in childhood inflammatory bowel disease, serum FGF23 was significantly higher in patients with IBD compared to controls (6)

How can you quantify circulating FGF23 levels?

FGF23 can easily be measured in blood samples (serum or plasma) with a conventional ELISA assay. The levels of FGF23 in the bloodstream consist of both the active intact hormone (iFGF23) and the inactive c-terminal fragments (cFGF23).

The C-terminal FGF23 assay captures both the intact FGF23 hormone and the fragments that form after FGF23 has been cleaved. The intact FGF23 assays utilize antibodies that are positioned in the N-terminal and C-terminal regions of the hormone, specifically targeting the biologically active intact FGF23.

Read more :  FGF23 an Overview

BIOMEDICA  FGF23 ELISA kits for  serum & plasma samples

FGF23 intact ELISA, # BI-20700

FGF23 (c-terminal) ELISA, # BI-20702

• developed & manufactured by Biomedica , Austria
• fully validated according to international quality guidelines
• numerous top journal citations

 

Related products : INTERLEUKIN-6  (IL-6) ELISA , #BI-IL6

• highly sensitive-measurable values in both serum and plasma
• ready to use calibrators and controls included

 

Literature

1. Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, van Goor H, van der Meulen-de Jong AE, Dijkstra G. Inflamm Bowel Dis. 2023 Feb 7:izad010. doi: 10.1093/ibd/izad010. Epub ahead of print. PMID: 36748574.
2. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. Kidney Int. 2016 Jan;89(1):135-46. doi: 10.1038/ki.2015.290. Epub 2016 Jan 4. PMID: 26535997; PMCID: PMC4854810.
3. Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Wheeler JA, Clinkenbeard EL. Curr Mol Biol Rep. 2019 Mar;5(1):8-17. doi: 10.1007/s40610-019-0110-9. Epub 2019 Jan 25. PMID: 31218207; PMCID: PMC6582956.
4. Regulation of FGF23: Beyond Bone. Simic P, Babitt JL.Curr Osteoporos Rep. 2021 Dec;19(6):563-573. doi: 10.1007/s11914-021-00703-w. Epub 2021 Nov 10. PMID: 34757587; PMCID: PMC8958553.
5. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Ghishan FK, Kiela PR. Am J Physiol Gastrointest Liver Physiol. 2011 Feb;300(2):G191-201. doi: 10.1152/ajpgi.00496.2010. Epub 2010 Nov 18. PMID: 21088237; PMCID: PMC3043650.
6. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. BMC Gastroenterol. 2012 May 2;12:44. doi: 10.1186/1471-230X-12-44. PMID: 22551310; PMCID: PMC3438067.